On Friday, DiaMedica Therapeutics Inc (NASDAQ: DMAC) was 6.36% up from the session before settling in for the closing price of $3.93. A 52-week range for DMAC has been $3.19 – $6.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 7.39%. When this article was written, the company’s average yearly earnings per share was at -29.44%. With a float of $24.15 million, this company’s outstanding shares have now reached $42.86 million.
The extent of productivity of a business whose workforce counts for 28 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
DiaMedica Therapeutics Inc (DMAC) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward DiaMedica Therapeutics Inc stocks. The insider ownership of DiaMedica Therapeutics Inc is 43.69%, while institutional ownership is 17.99%.
DiaMedica Therapeutics Inc (DMAC) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -29.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.05% during the next five years compared to 7.39% growth over the previous five years of trading.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) Trading Performance Indicators
You can see what DiaMedica Therapeutics Inc (DMAC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.65, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of DiaMedica Therapeutics Inc (DMAC)
The latest stats from [DiaMedica Therapeutics Inc, DMAC] show that its last 5-days average volume of 0.5 million was superior to 0.14 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 54.78%.
During the past 100 days, DiaMedica Therapeutics Inc’s (DMAC) raw stochastic average was set at 29.38%, which indicates a significant decrease from 75.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.34 in the past 14 days, which was higher than the 0.33 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.92, while its 200-day Moving Average is $4.70. Now, the first resistance to watch is $4.40. This is followed by the second major resistance level at $4.62. The third major resistance level sits at $4.88. If the price goes on to break the first support level at $3.92, it is likely to go to the next support level at $3.66. Assuming the price breaks the second support level, the third support level stands at $3.44.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) Key Stats
There are 42,883K outstanding shares of the company, which has a market capitalization of 179.25 million. As of now, sales total 0 K while income totals -24,440 K. Its latest quarter income was 0 K while its last quarter net income were -7,710 K.
